How to buy Athenex stock (ATNX)

Athenex is a biotechnology & medical research business based in the US. Athenex shares (ATNX) are listed on the NASDAQ and all prices are listed in US Dollars. Athenex employs 269 staff and has a trailing 12-month revenue of around $102.8 million.

Our top picks for where to buy Athenex stock

Buy Athenex stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Athenex stock price (NASDAQ: ATNX)

Use our graph to track the performance of ATNX stocks over time.

Athenex shares at a glance

• Key figures

Information last updated 2024-06-30.

52-week range	$0.00 - $0.00
50-day moving average more info button	$0.95
200-day moving average more info button	$3.35
Wall St. target price	$2.50
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-10.45

Is it a good time to buy Athenex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Athenex financials

Revenue TTM	$102.8 million
Gross profit TTM	$26.7 million
Return on assets TTM	-19.65%
Return on equity TTM	-1927.27%
Profit margin	-100.59%
Book value	$-0.75
Market Capitalization more info button	$2.3 million

TTM: trailing 12 months

Athenex share dividends

We're not expecting Athenex to pay a dividend over the next 12 months.

Have Athenex's shares ever split?

Athenex's shares were split on a 1:20 basis on 14 February 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Athenex shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Athenex shares which in turn could have impacted Athenex's share price.

Athenex share price volatility

Over the last 12 months, Athenex's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athenex's is 1.3452. This would suggest that Athenex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Athenex overview

Athenex, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors.

Frequently asked questions

null
What percentage of Athenex is owned by insiders or institutions?
Currently 9.733% of Athenex shares are held by insiders and 29.874% by institutions. How many people work for Athenex?
Latest data suggests 269 work at Athenex. When does the fiscal year end for Athenex?
Athenex's fiscal year ends in December. Where is Athenex based?
Athenex's address is: Conventus Building, Buffalo, NY, United States, 14203 What is Athenex's ISIN number?
Athenex's international securities identification number is: US04685N1037 What is Athenex's CUSIP number?
Athenex's Committee on Uniform Securities Identification Procedures number is: 04685N103